5-溴-2,3-二氢-1H-茚-2-羧酸 | 97901-15-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 5-溴-2,3-二氢-1H-茚-2-羧酸
• 英文名称: (S)-(+)-5-Bromo-2-indanoic acid
• 英文别名: 5-bromoindan-2-carboxylic acid；5-bromo-2-indancarboxylic acid；5-bromo-indan-2-carboxylic acid；5-Bromo-2,3-dihydro-1H-indene-2-carboxylic acid
• CAS: 97901-15-0
• 化学式: C₁₀H₉BrO₂
• 分子量: 241.084
• InChiKey: OMJPTHPPEYUYLP-UHFFFAOYSA-N

物化性质

• 沸点：
  370.8±42.0 °C(Predicted)
• 密度：
  1.640±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-溴-2,3-二氢-1H-茚-2-羧酸 在 硼烷四氢呋喃络合物 、 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 生成 5-Bromo-2,3-dihydro-1H-indene-2-carbaldehyde
  参考文献：
  名称：

  Potent MCH-1 receptor antagonists from cis-1,4-diaminocyclohexane-derived indane analogs

  摘要：

  Benzimidazole and indane are the two key fragments in our potent and selective MCH-1 receptor (MCHR1) antagonists. To identify novel linkers connecting the two fragments, we investigated diamino-cycloalkane-derived analogs and discovered highly potent antagonists with cis-1,4-diaminocyclohexane as a unique spacer in this chemical class. Structural overlay suggested that cis-1-substituted-4-aminocyclohexane functions as a bioisostere of 4-substituted-piperidine and that the active conformation adopts a U-shaped orientation. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.017
• 作为产物：
  描述：

  methyl 5-bromo-2,3-dihydro-1H-indene-2-carboxylate 在 sodium hydroxide 、 乙醚 、 二氯甲烷 、 水 、 Brine 、 magnesium sulfate 作用下， 以 溶剂黄146 为溶剂， 反应 16.0h， 以to give crude 5-bromo-indan-2-carboxylic acid的产率得到5-溴-2,3-二氢-1H-茚-2-羧酸
  参考文献：
  名称：

  IMIDAZOLE-2-THIONES

  摘要：

  公式1的化合物，其中X为S且变量的含义在规范中定义，具有特异性或选择性作用于alpha2B和/或alpha2C肾上腺素受体，而不是alpha2A肾上腺素受体，因此几乎没有心血管和/或镇静活性。这些公式1的化合物在哺乳动物中，包括人类，用作治疗对alpha2B肾上腺素受体激动剂有反应的疾病和/或缓解条件的药物。其中X为O的公式1的化合物也具有有利的特性，即它们几乎没有心血管和/或镇静活性，可用于治疗疼痛和其他几乎没有心血管和/或镇静活性的状况。

  公开号：

  US20080097103A1

文献信息

• [EN] 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS<br/>[FR] IMIDAZOLE-2-ONES ET IMIDAZOLE-2-THIONES 4 SUBSTITUES COMME AGONISTES DES ADRENO-RECEPTEURS ALPHA-2B ET ALPHA-2C
  申请人：ALLERGAN INC

  公开号：WO2003099795A1

  公开（公告）日：2003-12-04

  Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

  式(I)的化合物：其中X为S，变量的含义如规范中定义的那样，对alpha2B和/或alpha2C肾上腺素受体具有特异性或选择性，优先于alpha2A肾上腺素受体，并且因此具有无或仅有极小的心血管和/或镇静活性。这些式(I)的化合物在哺乳动物，包括人类中，作为药物用于治疗对alpha2B肾上腺素受体激动剂治疗有响应的疾病和/或缓解症状是有用的。式(I)的化合物，其中X为O，还具有有利的特性，即它们具有无或仅有极小的心血管和/或镇静活性，并且适用于治疗无或仅有极小的心血管和/或镇静活性的疼痛和其他症状。
• 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same
  申请人：Heidelbaugh M. Todd

  公开号：US20050075366A1

  公开（公告）日：2005-04-07

  The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha 2B adrenergic receptors in preference over alpha 2A and alpha 2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha 2B adrenergic receptors.

  该化学式的化合物，其中*表示一个不对称碳原子，对α2B肾上腺素受体具有特异性，优先于α2A和α2C肾上腺素受体，因此几乎没有或仅有极小的心血管和/或镇静活性。该化合物可用作哺乳动物，包括人类，治疗对α2B肾上腺素受体激动剂治疗敏感的疾病和/或缓解症状的药物。
• Certain [(1-imidazolyl)-lower-alkylene]-tetrahydronaphthalenecarboxylic
  申请人：Daiichi Seiyaku Co., Ltd.

  公开号：US04665188A1

  公开（公告）日：1987-05-12

  Benzocycloalkane derivatives of the formula (I) ##STR1## wherein: Z represents a methylene group or an ethylene group, either one of R.sup.1 and R.sup.2 represents --(CH.sub.2).sub.m --COOR.sup.3 and the other represents ##STR2## wherein R.sup.3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, n represents an interger of 1 to 6 and m represents an interger of 0 to 5, and the physiologically acceptable salts thereof; having a strong and selective inhibition activity of thromboxane A.sub.2 synthesis.

  苯并环烷衍生物的化学式（I）##STR1##其中：Z代表亚甲基团或乙烯基团，R.sup.1和R.sup.2中的一个代表--(CH.sub.2).sub.m --COOR.sup.3，另一个代表##STR2##其中R.sup.3代表氢原子或具有1至6个碳原子的烷基基团，n代表1至6的整数，m代表0至5的整数，以及其生理上可接受的盐；具有强大和选择性的抑制血栓素A.sub.2合成活性。
• MCH receptor antagonists
  申请人：Berthel Joseph Steven

  公开号：US20070078165A1

  公开（公告）日：2007-04-05

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.

  本文提供了以下式(I)的化合物及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗肥胖、暴饮暴食、焦虑、抑郁以及相关的疾病和疾病非常有用。
• 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
  申请人：——

  公开号：US20040220402A1

  公开（公告）日：2004-11-04

  Compounds of Formula 1 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha 2B and/or alpha 2C adrenergic receptors in preference over alpha 2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha 2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

  式11的化合物，其中X为S，变量的含义如规范中所定义的，对alpha2B和/或alpha2C肾上腺素受体具有特异性或选择性，而不是对alpha2A肾上腺素受体具有特异性，因此在心血管和/或镇静作用方面几乎没有或仅有最小的活性。这些式1的化合物在哺乳动物，包括人类中，用作治疗对alpha2B肾上腺素受体激动剂治疗有响应的疾病和/或缓解条件的药物。其中X为O的式1的化合物也具有有利的特性，即它们在心血管和/或镇静活性方面几乎没有或仅有最小的活性，并且可用于治疗疼痛和其他在心血管和/或镇静活性方面几乎没有或仅有最小的活性的疾病。